Psychiatric Comorbidity Reduces Quality of Life in Chronic Methadone Maintained Patients

REFERENCES

• Ward J, Hall W, Mattick RP. Role of maintenance treatment in opioid dependence. Lancet. 1999;353:221–226.
   PubMed Web of Science ®Google Scholar
• Millson PE, Challacombe L, Villeneuve PJ, . Self-perceived health among Canadian opiate users: a comparison to the general population and to other chronic disease populations. Can J Public Health. 2004;95:99–103.
   PubMed Web of Science ®Google Scholar
• Hser YI, Hoffman V, Grella CE, Anglin MD. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry. 2001;58:503–508.
   PubMed Web of Science ®Google Scholar
• Kleber HD, Weiss RD, Anton RF, Jr, . Treatment of patients with substance use disorders, second edition. American Psychiatric Association. Am J Psychiatry. 2007;164((4 Suppl)), 5–123.
   Google Scholar
• Smyth B, Fan J, Hser YI. Life expectancy and productivity loss among narcotics addicts thirty-three years after index treatment. J Addict Dis. 2006;25:37–47.
   PubMed Web of Science ®Google Scholar
• Marsden J, Gossop M, Stewart D, Rolfe A, Farrell M. Psychiatric symptoms among clients seeking treatment for drug dependence. Intake data from the National Treatment Outcome Research Study. Br J Psychiatry. 2000;176:285–289.
   PubMed Web of Science ®Google Scholar
• Brooner RK, King VL, Kidorf M, Schmidt CW, Jr, Bigelow GE. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry. 1997;54:71–80.
   PubMed Web of Science ®Google Scholar
• Ross J, Teesson M, Darke S, . The characteristics of heroin users entering treatment: findings from the Australian treatment outcome study (ATOS). Drug Alcohol Rev. 2005;24:411–418.
   PubMed Web of Science ®Google Scholar
• Kidorf M, Disney ER, King VL, Neufeld K, Beilenson PL, Brooner RK. Prevalence of psychiatric and substance use disorders in opioid abusers in a community syringe exchange program. Drug Alcohol Depend. 2004;74:115–122.
   PubMed Web of Science ®Google Scholar
• Teesson M, Havard A, Fairbairn S, Ross J, Lynskey M, Darke S. Depression among entrants to treatment for heroin dependence in the Australian Treatment Outcome Study (ATOS): prevalence, correlates and treatment seeking. Drug Alcohol Depend. 2005;78:309–315.
   PubMed Web of Science ®Google Scholar
• Peles E, Schreiber S, Naumovsky Y, Adelson M. Depression in methadone maintenance treatment patients: rate and risk factors. J Affect Disord. 2007;99:213–220.
   PubMed Web of Science ®Google Scholar
• Havard A, Teesson M, Darke S, Ross J. Depression among heroin users: 12-Month outcomes from the Australian Treatment Outcome Study (ATOS). J Subst Abuse Treat. 2006;30:355–362.
   PubMed Web of Science ®Google Scholar
• Callaly T, Trauer T, Munro L, Whelan G. Prevalence of psychiatric disorder in a methadone maintenance population. Aust N Z J Psychiatry. 2001;35:601–605.
   PubMed Web of Science ®Google Scholar
• Clark HW, Masson CL, Delucchi KL, Hall SM, Sees KL. Violent traumatic events and drug abuse severity. J Subst Abuse Treat. 2001;20:121–127.
   PubMed Web of Science ®Google Scholar
• Maremmani I, Pacini M, Pani PP, Perugi G, Deltito J, Akiskal H. The mental status of 1090 heroin addicts at entry into treatment: should depression be considered a ‘dual diagnosis’. Ann Gen Psychiatry. 2007;6:31–
   PubMedGoogle Scholar
• Kamal F, Flavin S, Campbell F, Behan C, Fagan J, Smyth R. Factors affecting the outcome of methadone maintenance treatment in opiate dependence. Ir Med J. 2007;100:393–397.
   PubMedGoogle Scholar
• Kidorf M, Brooner RK, King VL, Stoller KB, Wertz J. Predictive validity of cocaine, sedative, and alcohol dependence diagnoses. J Consult Clin Psychol. 1998;66:168–173.
   PubMed Web of Science ®Google Scholar
• Stenbacka M, Beck O, Leifman A, Romelsjo A, Helander A. Problem drinking in relation to treatment outcome among opiate addicts in methadone maintenance treatment. Drug Alcohol Rev. 2007;26:55–63.
   PubMed Web of Science ®Google Scholar
• Bovasso G, Cacciola J. The long-term outcomes of drug use by methadone maintenance patients. J Behav Health Serv Res. 2003;30:290–303.
   PubMed Web of Science ®Google Scholar
• Gelkopf M, Bleich A, Hayward R, Bodner G, Adelson M. Characteristics of benzodiazepine abuse in methadone maintenance treatment patients: a 1 year prospective study in an Israeli clinic. Drug Alcohol Depend. 1999;55:63–68.
   PubMed Web of Science ®Google Scholar
• Senbanjo R, Wolff K, Marshall J. Excessive alcohol consumption is associated with reduced quality of life among methadone patients. Addiction. 2007;102:257–263.
   PubMed Web of Science ®Google Scholar
• Epstein DH, Preston KL. Does cannabis use predict poor outcome for heroin-dependent patients on maintenance treatment? Past findings and more evidence against. Addiction. 2003;98:269–279.
   PubMed Web of Science ®Google Scholar
• Bramness JG, Kornor H. Benzodiazepine prescription for patients in opioid maintenance treatment in Norway. Drug Alcohol Depend. 2007;90:203–209.
   PubMed Web of Science ®Google Scholar
• King VL, Kidorf MS, Stoller KB, Carter JA, Brooner RK. Influence of antisocial personality subtypes on drug abuse treatment response. J Nerv Ment Dis. 2001;189:593–601.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Peles E, Adelson M. Association between improvement in depression, reduced benzodiazepine (BDZ) abuse, and increased psychotropic medication use in methadone maintenance treatment (MMT) patients. Drug Alcohol Depend. 2008;92:79–85.
   PubMed Web of Science ®Google Scholar
• Teplin D, O’Connell T, Daiter J, Varenbut M. A psychometric study of the prevalence of DSM IV personality disorders among office-based methadone maintenance patients. Am J Drug Alcohol Abuse. 2004;30:515–524.
   PubMed Web of Science ®Google Scholar
• Darke S, Finlay-Jones R, Kaye S, Blatt T. Anti-social personality disorder and response to methadone maintenance treatment. Drug Alcohol Rev. 1996;15:271–276.
   PubMed Web of Science ®Google Scholar
• Gossop M, Marsden J, Stewart D. Remission of psychiatric symptoms among drug misusers after drug dependence treatment. J Nerv Ment Dis. 2006;194:826–832.
   PubMed Web of Science ®Google Scholar
• Kessler RC. The epidemiology of dual diagnosis. Biol Psychiatry. 2004;56:730–737.
   PubMed Web of Science ®Google Scholar
• Rounsaville BJ, Kosten TR, Weissman MM, Kleber HD. Prognostic significance of psychopathology in treated opiate addicts. A 2.5-year follow-up study. Arch Gen Psychiatry. 1986;43:739–745.
   PubMed Web of Science ®Google Scholar
• Compton WM, III, Cottler LB, Jacobs JL, Ben-Abdallah A, Spitznagel EL. The role of psychiatric disorders in predicting drug dependence treatment outcomes. Am J Psychiatry. 2003;160:890–895.
   PubMed Web of Science ®Google Scholar
• Cacciola JS, Alterman AI, Rutherford MJ, McKay JR, Mulvaney FD. The relationship of psychiatric comorbidity to treatment outcomes in methadone maintained patients. Drug Alcohol Depend. 2001;61:271–280.
   PubMed Web of Science ®Google Scholar
• Disney E, Kidorf M, Kolodner K, . Psychiatric comorbidity is associated with drug use and HIV risk in syringe exchange participants. J Nerv Ment Dis. 2006;194:577–583.
   PubMed Web of Science ®Google Scholar
• Broome KM, Flynn PM, Simpson DD. Psychiatric comorbidity measures as predictors of retention in drug abuse treatment programs. Health Serv Res. 1999;34:791–806.
   PubMed Web of Science ®Google Scholar
• Fischer B, Rehm J, Kim G, Kirst M. Eyes wide shut?–A conceptual and empirical critique of methadone maintenance treatment. Eur Addict Res. 2005;11:1–9.
   PubMed Web of Science ®Google Scholar
• Karow A, Verthein U, Krausz M, Schafer I. Association of personality disorders, family conflicts and treatment with quality of life in opiate addiction. Eur Addict Res. 2008;14:38–46.
   PubMed Web of Science ®Google Scholar
• Puigdollers E, Domingo-Salvany A, Brugal MT, . Characteristics of heroin addicts entering methadone maintenance treatment: quality of life and gender. Subst Use Misuse. 2004;39:1353–1368.
   PubMed Web of Science ®Google Scholar
• Millson P, Challacombe L, Villeneuve PJ, . Determinants of health-related quality of life of opiate users at entry to low-threshold methadone programs. Eur Addict Res. 2006;12:74–82.
   PubMedGoogle Scholar
• Fischer B, Rehm J, Kim G. “Quality of Life” (QoL) in illicit opiate addiction research and treatment: concepts, evidence, questions. In: Westermann B, Jellinek C, Bellmann G, eds. Substitution: Zwischen Leben und Sterben. Weilheim, Germany: Beltz Deutscher Studienverlag; 2001:21–40.
   Google Scholar
• Sheehan DV, Lecrubier Y, Sheehan KH. The Mini International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl), 2022–2033.
   Google Scholar
• van Vliet I, de Beurs E. [The MINI International Neuropsychiatric Interview. A brief structured diagnostic psychiatric interview for DSM IV en ICD-10 psychiatric disorders]. Tijdschr Psychiatr. 2007;49:393–397.
   PubMedGoogle Scholar
• Cottler LB, Robins LN, Helzer JE. The reliability of the CIDI-SAM: a comprehensive substance abuse interview. Br J Addict. 1989;84:801–814.
   PubMedGoogle Scholar
• Pfohl B, Blum N, Zimmerman M. Structured Interview for DSM IV Personality Disorders. 1-9-1997 Washington, American Psychiatric Press.
   Google Scholar
• Damen KF, De Jong CA, Van der Kroft PJ. Interrater reliability of the structured interview for DSM IV personality in an opioid-dependent patient sample. Eur Addict Res. 2004;10:99–104.
   PubMed Web of Science ®Google Scholar
• McLellan AT, Luborsky L, Woody GE, O’Brien CP. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis. 1980;168:26–33.
   PubMed Web of Science ®Google Scholar
• Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53–72.
   PubMed Web of Science ®Google Scholar
• Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095–1108.
   PubMed Web of Science ®Google Scholar
• Szende A, Williams A. Measuring self-reported population health: an international perspective based on EQ-5D. Rotterdam: EuroQol Group; 2008.
   Google Scholar
• Eland-Goossensen A, Goor Ivd, Garretsen H, Schudel J. Screening for psychopathology in the clinical practice. J Subst Abuse Treat. 1997;14:585–591.
   Google Scholar
• Meulenbeek PA. Addiction problems and methadone treatment. J Subst Abuse Treat. 2000;19:171–174.
   Google Scholar
• Krabbe PF, Koning JP, Heinen N, Laheij RJ, van Cauter RM, De Jong CA. Rapid detoxification from opioid dependence under general anaesthesia versus standard methadone tapering: abstinence rates and withdrawal distress experiences. Addict Biol. 2003;8:351–358.
   PubMed Web of Science ®Google Scholar
• Essink-Bot ML, Stouthard M, Bonsel GJ. Generalisability of valuations on health states collected with the EuroQol questionnaire. Health Economics. 1993; 2237–2246.
   Google Scholar
• van de Willige G, Wiersma D, Nienhuis FJ, Jenner JA. Changes in quality of life in chronic psychiatric patients: a comparison between EuroQol (EQ-5D) and WHOQoL. Qual Life Res. 2005;14:441–451.
   Google Scholar
• Konig HH, Roick C, Angermeyer MC. Validity of the EQ-5D in assessing and valuing health status in patients with schizophrenic, schizotypal or delusional disorders. Eur Psychiatry. 2007;22:177–187.
   PubMed Web of Science ®Google Scholar
• Rutten-van Molken MP, Oostenbrink JB, Tashkin DP, Burkhart D, Monz BU. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages. Chest. 2006;130:1117–1128.
   Google Scholar
• Marra CA, Esdaile JM, Guh D, . A comparison of four indirect methods of assessing utility values in rheumatoid arthritis. Med Care. 2004;42:1125–1131.
   PubMed Web of Science ®Google Scholar
• Koopmanschap M. Coping with Type II diabetes: the patient’s perspective. Diabetologia. 2002;45:S18–S22.
   PubMed Web of Science ®Google Scholar
• Phillips J, Carpenter KM, Nunes EV. Suicide risk in depressed methadone-maintained patients: associations with clinical and demographic characteristics. Am J Addict. 2004;13:327–332.
   PubMed Web of Science ®Google Scholar
• Rehm J, Frick U, Hartwig C, Gutzwiller F, Gschwend P, Uchtenhagen A. Mortality in heroin-assisted treatment in Switzerland 1994–2000. Drug Alcohol Depend. 2005;79:137–143.
   PubMed Web of Science ®Google Scholar
• Hillebrand J, Marsden J, Finch E, Strang J. Excessive alcohol consumption and drinking expectations among clients in methadone maintenance. J Subst Abuse Treat. 2001;21:155–160.
   PubMed Web of Science ®Google Scholar
• Rittmannsberger H, Silberbauer C, Lehner R, Ruschak M. Alcohol consumption during methadone maintenance treatment. Eur Addict Res. 2000;6:2–7.
   PubMed Web of Science ®Google Scholar
• Buckley PF. Prevalence and consequences of the dual diagnosis of substance abuse and severe mental illness. J Clin Psychiatry. 2006;67(Suppl), 75–79.
   Google Scholar
• Mueser KT, Drake RE, Wallach MA. Dual diagnosis: a review of etiological theories. Addict Behav. 1998;23:717–734.
   PubMed Web of Science ®Google Scholar
• Maremmani I, Pani PP, Pacini M, Perugi G. Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients. J Subst Abuse Treat. 2007;33:91–98.
   PubMed Web of Science ®Google Scholar
• Gossop M, Marsden J, Stewart D, Kidd T. The National Treatment Outcome Research Study (NTORS): 4–5 year follow-up results. Addiction. 2003;98:291–303.
   PubMed Web of Science ®Google Scholar
• Connock M, Juarez-Garcia A, Jowett S, . Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess. 2007;11:1–171.
   PubMed Web of Science ®Google Scholar
• van den Brink W, Haasen C. Evidenced-based treatment of opioid-dependent patients. Can J Psychiatry. 2006;51:635–646.
   Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2003;2:CD002209–
   PubMedGoogle Scholar
• Woody GE. Research findings on psychotherapy of addictive disorders. Am J Addict. 2003;12(Suppl 2), S19–S26.
   Google Scholar
• Amato L, Minozzi S, Davoli M, Vecchi S, Ferri M, Mayet S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev. 2004;4:CD004147–
   Google Scholar
• Dijkgraaf MG, van der Zanden BP, de Borgie CA, Blanken P, van Ree JM, van den Brink W. Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials. BMJ. 2005;330:1297–
   PubMed Web of Science ®Google Scholar
• McCance-Katz EF. Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents. Clin Infect Dis. 2005;41(Suppl 1), S89–S95.
   Google Scholar